Out of the 160 profiled cell lines, nemtabrutinib most potently inhibited the viability of a chronic eosinophilic leukemia cell line (EoL-1), which expresses a chimeric kinase of FIP1L1 and PDGFRα (37) and is, according to the DepMap database (7), strongly dependent on SIK3. While the cellular IC50 profile of nemtabrutinib correlates with CRISPR dependency of SIK3, nemtabrutinib does not bind SIK3 in a biochemical kinase assay. This evidence concerns the gene FIP1L1 and Chronic Eosinophilic Leukemia, Not Otherwise Specified.